Medicure Inc. is a pharmaceutical company focused on the development commercialization and sale of cardiovascular drugs and the operation of a retail pharmacy business in the United States. The company was formed by the amalgamation of Medicure Inc. and Lariat Capital Inc. in December 1999 and continued under federal jurisdiction in February 2000. Its head office is located in Winnipeg Manitoba Canada. Medicure Inc. concentrates on the development commercialization and sale…
Medicure Inc. is a pharmaceutical company focused on the development commercialization and sale of cardiovascular drugs and the operation of a retail pharmacy business in the United States. The company was formed by the amalgamation of Medicure Inc. and Lariat Capital Inc. in December 1999 and continued under federal jurisdiction in February 2000. Its head office is located in Winnipeg Manitoba Canada. Medicure Inc. concentrates on the development commercialization and sale of cardiovascular drugs and the operation of a retail pharmacy business in the United States. The company's principal products are AGGRASTAT® for acute coronary syndrome and ZYPITAG® for hyperlipidemia and it owns Marley Drug Gateway Pharmacy and West Olympia Pharmacy which provide direct to consumer medication delivery across all 50 states.
Medicure Inc. generates revenue from the sale of AGGRASTAT® to drug wholesalers who then supply hospitals for administration to patients. Net AGGRASTAT® product sales were $5.7 million for the year ended December 31 2025 compared to $8.1 million for the year ended December 31 2024. The company also sells ZYPITAMAG® through wholesalers to pharmacies and through its e commerce pharmacy platforms. Net ZYPITAMAG® product sales through the traditional insured channel were $2.8 million for the year ended December 31 2025 compared to $3.0 million for the year ended December 31 2024. In addition Marley Drug contributed $12.8 million of net revenue for the year ended December 31 2025 versus $10.8 million for the year ended December 31 2024. Of Marley Drug's revenue $3.7 million was attributable to ZYPITAMAG® sales in 2025 and $3.2 million in 2024. Gateway Pharmacy added $2.8 million of net revenue for the year ended December 31 2025 and West Olympia Pharmacy added $4.7 million of net revenue for the same period. The company's direct to consumer e commerce service ships FDA approved medications nationwide and contributes to overall pharmacy revenue. The company's research and development activities do not currently produce revenue but are intended to support future product approvals and potential milestone payments.
The company operates through the following segments:.
- Cardiovascular Products segment includes the development manufacturing and marketing of AGGRASTAT® and ZYPITAMAG® including regulatory brand and life cycle management activities for sale to wholesalers hospitals and pharmacies.
- Pharmacy Business Segment segment operates Marley Drug Gateway Pharmacy and West Olympia Pharmacy providing direct to patient medication delivery e commerce services nationwide access to prescription and over the counter drugs and features automated pill dispensing an extended supply generic drug program and an effective customer communication system.
In the anti thrombotic market AGGRASTAT® competes with established glycoprotein IIb/IIIa inhibitors such as eptifibatide (Integrilin®) abciximab (ReoPro®) and tirofiban itself and faces pressure from generic alternatives including generic eptifibatide and generic tirofiban following the expiration of its patent in 2023. The launch of the intravenous antiplatelet agent cangrelor (Kengreal TM) and the growing use of oral antiplatelet agents ticagrelor (Brilinta®) and prasugrel (Effient®) also influence the competitive landscape. ZYPITAMAG® operates in the competitive antihyperlipidemic arena where it contends with other statins and generic pitavastatin calcium while benefiting from its low cost profile and availability through the company's direct to consumer pharmacy channels. The company's pharmacy business holds a strong position due to Marley Drug's extensive nationwide customer base automated pill dispensing extended supply generic drug program and effective customer communication system which enables it to serve patients without insurance and compete effectively against traditional retail chains supermarkets mass merchandisers and online retailers such as Cost Plus Drugs and Amazon. The company leverages guideline recommendations from the AHA and ACC that support the use of AGGRASTAT® in non ST elevation acute coronary syndrome to maintain its hospital customer base.
Medicure Inc. serves hospitals that administer AGGRASTAT® to patients experiencing non ST elevation acute coronary syndrome and related acute coronary conditions. The company's cardiovascular products are distributed to pharmacies and other healthcare providers through wholesale drug distributors. Marley Drug Gateway Pharmacy and West Olympia Pharmacy provide direct to patient medication delivery including ZYPITAMAG® and other prescription and over the counter drugs to individual consumers across all 50 states Washington D C and Puerto Rico. The pharmacy segment also serves customers who prefer to obtain medications without the need for insurance through its cost competitive pricing and direct to consumer e commerce platform. Wholesale distributors remain a key customer link for the company's AGGRASTAT® and ZYPITAMAG® products ensuring broad reach to hospital and retail pharmacy networks.